NIMG-26. DIAGNOSIS OF PSEUDOPROGRESSION FOLLOWING RADIOTHERAPY PLUS LOMUSTINE-TEMOZOLOMIDE CHEMOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS USING FET PET

BACKGROUND: The CeTeG/NOA-09 trial demonstrated a significant survival benefit of radiotherapy plus lomustine-temozolomide chemotherapy in glioblastoma patients with methylated O(6)-methylguanine-DNA-methyltransferase (MGMT) promoter compared to standard temozolomide chemoradiation (1). However, dat...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Neuro Oncol
Main Authors: Werner, Jan-Michael, Ceccon, Garry, Weller, Johannes, Schaub, Christina, Tscherpel, Caroline, Lohmann, Philipp, Bauer, Elena, Schäfer, Niklas, Stoffels, Gabriele, Kabbasch, Christoph, Baues, Christian, Marnitz, Simone, Fink, Gereon R, Langen, Karl-Josef, Herrlinger, Ulrich, Galldiks, Norbert
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2020
Teme:
Neuroimaging
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651124/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.639
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki